Fml (fluorometholone)

Fluorometholone and fluorometholone acetate are applied topically to the eye. Care should be taken to avoid contamination of the tip of the dropper or ointment tube.

One drop of the 0.1% or 0.25% ophthalmic suspension (containing fluorometholone) may be instilled into the conjunctival sac of the affected eye(s) 2-4 times daily or 1.3 cm (1/2 inch) of the 0.1% ointment may be applied in the conjunctival sac of the affected eye(s) 1-3 times daily. During the initial 24-48 hours of therapy with fluorometholone 0.1% suspension or ointment, dosage may be increased to 1 drop of suspension or 1.3 cm of ointment every 4 hours. If improvement does not occur within several days, the drug should be discontinued and other therapy begun. The duration of treatment depends on the type and severity of the disease and may range from a few days to several weeks; long-term therapy should be avoided. When the drug is discontinued, dosage should be gradually tapered to avoid exacerbation of the disease.

When fluorometholone acetate is used, 1 to 2 drops of the 0.1% ophthalmic suspension may be instilled into the conjunctival sac 4 times daily. During the initial 24-48 hours of therapy, dosage may be increased to 2 drops every 2 hours. If improvement does not occur after 2 weeks, patients should contact a clinician; fluorometholone acetate therapy should not be discontinued prematurely.

One drop of the suspension containing a fixed combination of fluorometholone and sulfacetamide sodium may be instilled into the lower conjunctival sac 4 times daily. When the suspension containing a fixed combination of fluorometholone acetate and tobramycin is used, 1 or 2 drops may be instilled into the conjunctival sac every 4-6 hours; during the initial 24-48 hours of therapy, dosage may be increased to 1 or 2 drops every 2 hours. Therapy should not be discontinued prematurely.

Patients should initially receive a prescription for 20 mL or less of suspension or 8 g or less of ointment and should be reevaluated by their clinician prior to obtaining a refill.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

• Fungal infection of eye
• Herpes simplex dendritic keratitis
• Tuberculosis of the eye
• Vaccinia virus keratitis

• Amebic infection of the eye
• Ocular hypertension

• Corneal erosion
• Diabetes mellitus
• Krukenberg spindle
• Open angle glaucoma
• Severe myopia

There is no enhanced messaging for this drug.

Less Frequent

• Ocular hypertension

Rare or Very Rare

• Adrenocortical insufficiency
• Cataracts
• Central serous chorioretinopathy
• Corneal degeneration
• Corneal edema
• Corneal erosion
• Corneal ulcer
• Fungal infection of eye
• Glaucoma
• Globe perforation
• Hypercortisolism
• Hypersensitivity drug reaction
• Keratitis
• Optic nerve damage
• Punctate keratitis
• Reduced visual acuity
• Uveitis
• Visual changes
• Visual field defect

More Frequent

• Blurred vision

Less Frequent

• Headache disorder
• Iritis
• Ocular pain

Rare or Very Rare

• Accommodation disorder
• Allergic dermatitis
• Blepharoptosis
• Calcification of cornea
• Chemosis
• Conjunctival hyperemia
• Conjunctivitis
• Dizziness
• Dysgeusia
• Eye tearing
• Foreign body sensation of eye
• Impaired wound healing
• Mydriasis
• Ocular infection
• Ocular irritation
• Ocular itching
• Ocular redness
• Photophobia
• Urticaria

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.